C
Ligand Pharmaceuticals Incorporated LGND
$193.03 -$2.07-1.06% NASDAQ
Recommendation
Prev Close
$195.10
Volume
218,276
Avg Vol (90D)
224,049
Market Cap
$3.84B
Dividend & Yield
--
52-Week Range
$93.58 - $212.49
P/E (TTM)
94.40
EPS (TTM)
$2.07
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $91,457.28 in Stock
12/3/2025 - Ticker Report
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Granite Investment Partners LLC
12/3/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Purchased by Russell Investments Group Ltd.
12/2/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by Brokerages
12/2/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Legal & General Group Plc
12/1/2025 - MarketBeat
Will Lower Short Interest Reshape Ligand Pharmaceuticals' (LGND) Sentiment Among Industry Peers?
11/30/2025 - Simply Wall St
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Loomis Sayles & Co. L P
11/30/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by SG Americas Securities LLC
11/30/2025 - MarketBeat
Advantage Alpha Capital Partners LP Purchases New Stake in Ligand Pharmaceuticals Incorporated $LGND
11/29/2025 - MarketBeat
Peering Into Ligand Pharmaceuticals Inc's Recent Short Interest
11/28/2025 - Benzinga
Intech Investment Management LLC Sells 1,711 Shares of Ligand Pharmaceuticals Incorporated $LGND
11/27/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH
11/26/2025 - MarketBeat
Ligand Pharmaceuticals (LGND, $199.03) Moving Average Convergence Divergence (MACD) Histogram turned negative on November 20, 2025
11/21/2025 - Tickeron - Stocks
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
11/19/2025 - Yahoo! Finance: News
What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?
11/19/2025 - Insider Monkey
Should Ligand Pharmaceuticals' (LGND) Surging Earnings and Raised Outlook Prompt Investors to Reassess Their Strategy?
11/19/2025 - Simply Wall St
Virtual Meeting Set for Ligand Pharmaceuticals (LGND) on November 25
11/18/2025 - GuruFocus
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year
11/18/2025 - Investor's Business Daily
This Fund Sold $9 Million of Ligand Stock After an 84% Rally What Investors Should Know
11/17/2025 - Fool.com Headlines
Ligand Pharmaceuticals (LGND): Evaluating Valuation After Recent 11% Share Price Gain
11/17/2025 - Simply Wall St
Ligand Pharmaceuticals Incorporated $LGND Position Decreased by Calamos Advisors LLC
11/16/2025 - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Sold by Impax Asset Management Group plc
11/14/2025 - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?
11/13/2025 - MarketBeat
Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come
11/13/2025 - SeekingAlpha
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
11/11/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$251.23M
EBITDA (TTM)
$63.03M
EBIT (TTM)
$28.85M
Net Income (TTM)
$48.58M
Balance Sheet
Total Assets (Q)
$1.48B
Total Debt (Q)
$451.00M
Total Liabilities (Q)
$526.60M
Book Value Per Share (Q)
$48.34
Cash Flow
Cash from Operations (TTM)
$31.92M
Cash from Investing (TTM)
-$397.84M
Cash from Financing (TTM)
$440.28M
Net Change in Cash (TTM)
$75.76M
Filings
Filing Date
Friday, November 7, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Feb 23 and 27 (est)
Price History
Loading...
Beta
1.08
7-Day Total Return
-3.11%
30-Day Total Return
3.41%
60-Day Total Return
16.70%
90-Day Total Return
43.07%
Year to Date Total Return
78.04%
1-Year Total Return
60.95%
2-Year Total Return
222.42%
3-Year Total Return
176.94%
5-Year Total Return
250.35%
52-week Low
Apr 09, 2025 - $93.58
52-week High
Nov 11, 2025 - $212.49
Valuation
Market Cap
$3.84B - Mid Cap
Enterprise Value
$3.63B
Price/Sales (TTM)
16.02
Price/Book (Q)
4.04
Dividends and Shares
Shares Outstanding
20.63
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.ligand.com
Phone Number
858 550 7500
Address
555 Heritage Drive
Jupiter, FL 33458
Country
United States
Year Founded
1987
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed